Sai Parenterals Files 25th Annual Report for FY 2025-26

Sai Parenterals Ltd has submitted its 25th Annual Report for the Financial Year 2025-26, in compliance with SEBI (LODR) Regulations, 2015. The report, dispatched to shareholders on August 19, 2026, details the company's evolution into an integrated pharmaceutical platform with strengths in branded generics and a scaling CDMO business. The company highlights its growing focus on injectables, R&D investments, and a manufacturing network with 1,160 million units of installed annual capacity across five facilities. International expansion through Noumed in Australia and New Zealand, including a renewed ₹1,300 Crore OTC medicines supply agreement, is also a key focus. The Annual General Meeting is scheduled for September 10, 2026, via Video Conference.